HCPLive Network

FDA Approves Zecuity Skin Patch to Treat Migraine

 
TUESDAY, Jan. 22 (HealthDay News) -- Zecuity, a sumatriptan iontophoretic single-use, battery-powered transdermal system, has been approved by the U.S. Food and Drug Administration for acute treatment of migraine with or without aura in adults.

Noting that migraine patients often present with additional symptoms including migraine-related nausea, Zecuity patches provide an non-oral route of administration. Zecuity patches are applied to the upper arm or thigh and, on activation, initiate transdermal delivery of 6.5 mg sumatriptan over a four-hour period.

The safety and effectiveness of Zecuity were assessed in phase 3 trials that included more than 800 patients who used more than 10,000 patches. After two hours, 18 percent of patients who used Zecuity patches had no more headache, 53 percent experienced some headache relief, and 84 percent had no more nausea. For patients who used a placebo patch, the corresponding figures were 9, 29, and 63 percent. Side effects included application site pain, tingling, itching, and discomfort (5 percent), and triptan-associated adverse events (atypical sensations, 2 percent; pain and other pressure sensations, 2 percent).

"Migraine-related nausea can be as debilitating as migraine headache pain itself," study investigator Stephen D. Silberstein, M.D., of the Jefferson Headache Center in Philadelphia, said in a statement. "Treatments bypassing the gastrointestinal tract may be the best way to treat these patients."
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Even though the active ingredient in marijuana can be associated with memory impairment, it may slow or halt Alzheimer’s disease.
Simply shifting from manual to electronic transactions for just 6 processes could save physicians and other healthcare providers billions of dollars.
Peripheral neuropathy was found in a third of HIV patients in a recent study of 58 men with a median age of 36 years.
Men who are socially well-integrated show more than a 2-fold reduced risk of suicide, according to a longitudinal study published in the Annals of Internal Medicine.
When a patient gets bitten by a dog, there can be many issues doctors need to confront as treatment begins. Two doctors shared their experiences of a patient who was bitten by a dog and still had symptoms including swelling and pain 2 weeks after his K-9 encounter.
A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online Aug. 28 in Diabetologia.
The costs of Medicare associated with Sovaldi (sofosbuvir), an emerging hepatitis C drug, will vary depending on how many people are given the treatment, a blog in Health Affairs found.
More Reading